Efficacy and safety of a new triple-combination agent for the treatment of facial melasma

Susan C. Taylor, Helen Torok, Terry Jones, Nicholas Lowe, Phoebe Rich, Eduardo Tschen, Alan Menter, Leslie Baumann, Joshua J. Wieder, Michael M. Jarratt, David Pariser, Dale Martin, Jonathan Weiss, Joel Shavin, Nini Ramirez

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Treatment of melasma, a hyperpigmentation disorder, remains a challenge. The primary objective of two 8-week, multicenter, randomized, investigator-blind studies was to compare the efficacy and safety of a hydrophilic cream formulation containing tretinoin 0.05%, hydroquinone 4.0%, and fluocinolone acetonide 0.01% (RA+HQ+FA) with the dual-combination agents tretinoin plus hydroquinone (RA+HQ), tretinoin plus fluocinolone acetonide (RA+FA), and hydroquinone plus fluocinolone acetonide (HQ+FA). All agents had the same drug concentration and vehicle. A total of 641 adult patients, predominantly female, with moderate to severe melasma and Fitzpatrick skin types I through IV, were randomized to the various treatment groups. Due to the similarity of the study designs, the results of the 2 studies were combined and are reported here. The primary efficacy analysis involved the proportion of intent-to-treat patients in each treatment group whose condition had completely cleared by week 8. The results of the combined clinical trials demonstrated that significantly more of the patients treated with RA+HQ+FA (26.1%) experienced complete clearing compared with the other treatment groups (4.6%) at the end of week 8 (P<.0001). In addition, at week 8, a 75% reduction in melasma/pigmentation was observed in more than 70% of patients treated with RA+HQ+FA compared with 30% in patients treated with the dual-combination agents. The most common adverse reactions seen with all treatment groups were erythema, skin peeling, burning, and/or stinging sensation. The majority of treatment-related adverse events were of mild severity.

Original languageEnglish (US)
Pages (from-to)67-72
Number of pages6
JournalCutis
Volume72
Issue number1
StatePublished - Jul 1 2003
Externally publishedYes

Fingerprint

Melanosis
Fluocinolone Acetonide
Safety
Tretinoin
Therapeutics
Skin
Hyperpigmentation
Pigmentation
Erythema
Research Personnel
Clinical Trials
formaldehyde-hydroquinone polymer
Pharmaceutical Preparations
hydroquinone

ASJC Scopus subject areas

  • Dermatology

Cite this

Taylor, S. C., Torok, H., Jones, T., Lowe, N., Rich, P., Tschen, E., ... Ramirez, N. (2003). Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis, 72(1), 67-72.

Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. / Taylor, Susan C.; Torok, Helen; Jones, Terry; Lowe, Nicholas; Rich, Phoebe; Tschen, Eduardo; Menter, Alan; Baumann, Leslie; Wieder, Joshua J.; Jarratt, Michael M.; Pariser, David; Martin, Dale; Weiss, Jonathan; Shavin, Joel; Ramirez, Nini.

In: Cutis, Vol. 72, No. 1, 01.07.2003, p. 67-72.

Research output: Contribution to journalArticle

Taylor, SC, Torok, H, Jones, T, Lowe, N, Rich, P, Tschen, E, Menter, A, Baumann, L, Wieder, JJ, Jarratt, MM, Pariser, D, Martin, D, Weiss, J, Shavin, J & Ramirez, N 2003, 'Efficacy and safety of a new triple-combination agent for the treatment of facial melasma', Cutis, vol. 72, no. 1, pp. 67-72.
Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003 Jul 1;72(1):67-72.
Taylor, Susan C. ; Torok, Helen ; Jones, Terry ; Lowe, Nicholas ; Rich, Phoebe ; Tschen, Eduardo ; Menter, Alan ; Baumann, Leslie ; Wieder, Joshua J. ; Jarratt, Michael M. ; Pariser, David ; Martin, Dale ; Weiss, Jonathan ; Shavin, Joel ; Ramirez, Nini. / Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. In: Cutis. 2003 ; Vol. 72, No. 1. pp. 67-72.
@article{f67e4d1d01d7461d92913ac822d30b86,
title = "Efficacy and safety of a new triple-combination agent for the treatment of facial melasma",
abstract = "Treatment of melasma, a hyperpigmentation disorder, remains a challenge. The primary objective of two 8-week, multicenter, randomized, investigator-blind studies was to compare the efficacy and safety of a hydrophilic cream formulation containing tretinoin 0.05{\%}, hydroquinone 4.0{\%}, and fluocinolone acetonide 0.01{\%} (RA+HQ+FA) with the dual-combination agents tretinoin plus hydroquinone (RA+HQ), tretinoin plus fluocinolone acetonide (RA+FA), and hydroquinone plus fluocinolone acetonide (HQ+FA). All agents had the same drug concentration and vehicle. A total of 641 adult patients, predominantly female, with moderate to severe melasma and Fitzpatrick skin types I through IV, were randomized to the various treatment groups. Due to the similarity of the study designs, the results of the 2 studies were combined and are reported here. The primary efficacy analysis involved the proportion of intent-to-treat patients in each treatment group whose condition had completely cleared by week 8. The results of the combined clinical trials demonstrated that significantly more of the patients treated with RA+HQ+FA (26.1{\%}) experienced complete clearing compared with the other treatment groups (4.6{\%}) at the end of week 8 (P<.0001). In addition, at week 8, a 75{\%} reduction in melasma/pigmentation was observed in more than 70{\%} of patients treated with RA+HQ+FA compared with 30{\%} in patients treated with the dual-combination agents. The most common adverse reactions seen with all treatment groups were erythema, skin peeling, burning, and/or stinging sensation. The majority of treatment-related adverse events were of mild severity.",
author = "Taylor, {Susan C.} and Helen Torok and Terry Jones and Nicholas Lowe and Phoebe Rich and Eduardo Tschen and Alan Menter and Leslie Baumann and Wieder, {Joshua J.} and Jarratt, {Michael M.} and David Pariser and Dale Martin and Jonathan Weiss and Joel Shavin and Nini Ramirez",
year = "2003",
month = "7",
day = "1",
language = "English (US)",
volume = "72",
pages = "67--72",
journal = "Cutis",
issn = "0011-4162",
publisher = "Quadrant Healthcom Inc.",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of a new triple-combination agent for the treatment of facial melasma

AU - Taylor, Susan C.

AU - Torok, Helen

AU - Jones, Terry

AU - Lowe, Nicholas

AU - Rich, Phoebe

AU - Tschen, Eduardo

AU - Menter, Alan

AU - Baumann, Leslie

AU - Wieder, Joshua J.

AU - Jarratt, Michael M.

AU - Pariser, David

AU - Martin, Dale

AU - Weiss, Jonathan

AU - Shavin, Joel

AU - Ramirez, Nini

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Treatment of melasma, a hyperpigmentation disorder, remains a challenge. The primary objective of two 8-week, multicenter, randomized, investigator-blind studies was to compare the efficacy and safety of a hydrophilic cream formulation containing tretinoin 0.05%, hydroquinone 4.0%, and fluocinolone acetonide 0.01% (RA+HQ+FA) with the dual-combination agents tretinoin plus hydroquinone (RA+HQ), tretinoin plus fluocinolone acetonide (RA+FA), and hydroquinone plus fluocinolone acetonide (HQ+FA). All agents had the same drug concentration and vehicle. A total of 641 adult patients, predominantly female, with moderate to severe melasma and Fitzpatrick skin types I through IV, were randomized to the various treatment groups. Due to the similarity of the study designs, the results of the 2 studies were combined and are reported here. The primary efficacy analysis involved the proportion of intent-to-treat patients in each treatment group whose condition had completely cleared by week 8. The results of the combined clinical trials demonstrated that significantly more of the patients treated with RA+HQ+FA (26.1%) experienced complete clearing compared with the other treatment groups (4.6%) at the end of week 8 (P<.0001). In addition, at week 8, a 75% reduction in melasma/pigmentation was observed in more than 70% of patients treated with RA+HQ+FA compared with 30% in patients treated with the dual-combination agents. The most common adverse reactions seen with all treatment groups were erythema, skin peeling, burning, and/or stinging sensation. The majority of treatment-related adverse events were of mild severity.

AB - Treatment of melasma, a hyperpigmentation disorder, remains a challenge. The primary objective of two 8-week, multicenter, randomized, investigator-blind studies was to compare the efficacy and safety of a hydrophilic cream formulation containing tretinoin 0.05%, hydroquinone 4.0%, and fluocinolone acetonide 0.01% (RA+HQ+FA) with the dual-combination agents tretinoin plus hydroquinone (RA+HQ), tretinoin plus fluocinolone acetonide (RA+FA), and hydroquinone plus fluocinolone acetonide (HQ+FA). All agents had the same drug concentration and vehicle. A total of 641 adult patients, predominantly female, with moderate to severe melasma and Fitzpatrick skin types I through IV, were randomized to the various treatment groups. Due to the similarity of the study designs, the results of the 2 studies were combined and are reported here. The primary efficacy analysis involved the proportion of intent-to-treat patients in each treatment group whose condition had completely cleared by week 8. The results of the combined clinical trials demonstrated that significantly more of the patients treated with RA+HQ+FA (26.1%) experienced complete clearing compared with the other treatment groups (4.6%) at the end of week 8 (P<.0001). In addition, at week 8, a 75% reduction in melasma/pigmentation was observed in more than 70% of patients treated with RA+HQ+FA compared with 30% in patients treated with the dual-combination agents. The most common adverse reactions seen with all treatment groups were erythema, skin peeling, burning, and/or stinging sensation. The majority of treatment-related adverse events were of mild severity.

UR - http://www.scopus.com/inward/record.url?scp=0141993673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141993673&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 67

EP - 72

JO - Cutis

JF - Cutis

SN - 0011-4162

IS - 1

ER -